Syndax Pharmaceuticals
Syndax Pharmaceuticals, a Waltham-based biopharmaceutical company, specializes in cancer therapies.
Syndax Pharmaceuticals, a Waltham-based biopharmaceutical company, specializes in cancer therapies.
Syndax Pharmaceuticals, founded in Waltham, Massachusetts, is a biopharmaceutical company dedicated to advancing the next generation of targeted cancer treatments. Their core mission is to develop innovative therapies that enable people with cancer to live longer and better lives. Syndax focuses on treating solid tumors and hematological cancers, including lung and breast cancer. Their product pipeline includes first-in-class therapies such as Revumenib, which is currently being evaluated in clinical trials for acute leukemias.
Notable affiliates include leading oncologists and researchers who contribute to their robust clinical programs. Syndax has garnered significant investment from prominent healthcare venture capital firms, supporting its ambitious research and development efforts. Key achievements include presenting positive data from their BEAT AML and AUGMENT-101 combination trials at major medical congresses. Syndax's impact lies in its potential to transform cancer treatment paradigms, offering hope to patients through cutting-edge therapeutic options.
Companies similar to Syndax Pharmaceuticals include SynerGene Therapeutics, Blueprint Medicines, Athenex and G1 Therapeutics.
Syndax Pharmaceuticals was founded in 2005.
Syndax Pharmaceuticals' headquarters is located in Waltham, MA, US.
Syndax Pharmaceuticals' most recent funding round was for $230M (USD) in December 2023.
As of Dec 14, 2023, Syndax Pharmaceuticals has raised a total of $803.6M (USD).
Syndax Pharmaceuticals has 107 employees as of Feb 6, 2024.
